US Edition
Phase II Clinical Trial Data of CX11/VCT220 in China Was Released at ADA 2025 "` – EastMud
Summary by eastmud.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Patients treated with CX11 (also known as VCT220) had a 9.7% and 9.4% reduction in body weight from baseline after 16 weeks in the fast and slow titration groups, respectively (p≤0.001). The results showed good tolerability and no drug-induced liver injury was observed. (SeaPRwire) – Berkeley Heights, NJ and Shanghai, June 23, 2025 – Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company committed to developing inn…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
